{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:20:04Z","timestamp":1785860404780,"version":"3.56.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Standardized chemotherapy-induced nausea and vomiting (CINV) prevention in HEC is critical, yet NK1RAs remain inaccessible for some patients due to cost and availability. Our prior study demonstrated HXZQ\u2005+\u20055HT3RAs\u2005+\u2005dexamethasone\u2019s superior efficacy; this phase III trial aimed to validate this regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This multicenter, double-blind, randomized phase III trial (10 hospitals, Southwest China; March 2023\u2013August 2024) assigned patients to group HX (HXZQ\u2005+\u20055HT3RA\u2005+\u2005dexamethasone) or group C (control). Primary endpoints: mean No CINV Days (NCDs) during the full cycle and complete control (CC) rate beyond the risk period. Secondary endpoints: safety, CC rate during the risk period, mean no nausea days and life function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 166 patients were enrolled and 139 patients completed the study, 73 in group HX and 66 in group C. The mean NCDs was significantly better in group HX (17.92\u2005\u00b1\u20054.06) than that in group C (15.26\u2005\u00b1\u20055.91,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.002). Group HX showed better NCDs in acute, delayed and the period beyond the risk phases than group C, with a higher CC rate of CINV beyond the risk phase (80.8% vs 60.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.009). The mean no nausea days in group HX was significantly better than that in group C (18.26 vs 15.45,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.001). Group HX also showed a trend to better functional living index-emesis score, but only achieved the significance during the period beyond the risk phase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>HXZQ in combination with a 5-HT3 receptor antagonist and dexamethasone is safe and feasible for preventing CINV due to 3-day cisplatin-containing HEC throughout the whole cycle.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046778","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T21:02:05Z","timestamp":1766782925000},"page":"e46778","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A randomized, controlled, multicenter phase III clinical trial of Huo Xiang Zheng Qi oral liquid for the prevention and control of nausea and vomiting caused by multiday cisplatin-based regimen"],"prefix":"10.1097","volume":"104","author":[{"given":"Liping","family":"Tong","sequence":"first","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University\/Department of medical oncology, Shangjin Nanfu Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songze","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Ye","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People\u2019s Hospital (The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Center of 903 Hospital, City of Jiangyou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of oncology, the second people\u2019s hospital of Yibin, Yibin, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianguo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Chengdu 363 Hospital of Southwest Medical University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Suining Central Hospital, Suining, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taifang","family":"Peng","sequence":"additional","affiliation":[{"name":"Chongqing University Qianjiang Hospital\/ Qianjiang Central Hospital of Chongqing, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Oncology Department, The First Afffliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Xia","sequence":"additional","affiliation":[{"name":"West China-Guang\u2019An Hospital, Sichuan University, Guang\u2019an, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengjin","family":"Hu","sequence":"additional","affiliation":[{"name":"Oncology Department, Qianjiang National Hospital, Qianjiang, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Biotherapy Research, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xian","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University\/Department of medical oncology, Shangjin Nanfu Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[{"name":"Cancer Center of 903 Hospital, City of Jiangyou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cancer Prevention and Treatment Institute of Chengdu, Chengdu Fifth People\u2019s Hospital (The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine), Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Radiotherapy Physics and Technology Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5496-8450","authenticated-orcid":false,"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University\/Department of medical oncology, Shangjin Nanfu Hospital, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251226","doi-asserted-by":"crossref","first-page":"2287966","DOI":"10.1080\/10717544.2023.2287966","article-title":"Platinum-based drugs and hydrogel: a promising anti-tumor combination.","volume":"30","author":"Yao","year":"2023","journal-title":"Drug Deliv"},{"key":"R2-20251226","doi-asserted-by":"crossref","first-page":"750507","DOI":"10.3389\/fphar.2022.750507","article-title":"Mechanisms of chemotherapy-induced neurotoxicity.","volume":"13","author":"Was","year":"2022","journal-title":"Front Pharmacol"},{"key":"R3-20251226","first-page":"100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends.","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"R4-20251226","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"R5-20251226","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update.","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"R6-20251226","first-page":"30","article-title":"2023 MASCC\/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies.","volume":"32","author":"Molassiotis","year":"2024","journal-title":"Support Care Cancer"},{"key":"R7-20251226","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1002\/onco.13716","article-title":"Practice patterns for prevention of chemotherapy\u2010induced nausea and vomiting and antiemetic guideline adherence based on real\u2010world prescribing data.","volume":"26","author":"Aapro","year":"2021","journal-title":"Oncologist"},{"key":"R8-20251226","doi-asserted-by":"crossref","first-page":"e7121","DOI":"10.1002\/cam4.7121","article-title":"Retrospective analysis of real\u2010world prescribing data for managing cisplatin\u2010based chemotherapy\u2010induced nausea and vomiting in China.","volume":"13","author":"Si","year":"2024","journal-title":"Cancer Med"},{"key":"R9-20251226","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00432-024-05766-7","article-title":"Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting.","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"R10-20251226","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.2217\/fon-2021-1523","article-title":"Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting.","volume":"18","author":"Li","year":"2022","journal-title":"Future Oncol (London, England)"},{"key":"R11-20251226","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","article-title":"Cancer treatments: past, present, and future.","volume":"286-287","author":"Sonkin","year":"2024","journal-title":"Cancer Genetics"},{"key":"R12-20251226","doi-asserted-by":"crossref","first-page":"23548","DOI":"10.26717\/BJSTR.2020.30.004979","article-title":"Effect of traditional medicine on clinical cancer.","volume":"30","author":"Liu","year":"2020","journal-title":"Biomed J Scientific Techn Res"},{"key":"R13-20251226","first-page":"176","article-title":"Research progress in chemotherapy-related nausea and vomiting in traditional Chinese and western medicine.","volume":"22","author":"Zewen","year":"2024","journal-title":"Chin And Foreign Med Res"},{"key":"R14-20251226","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1186\/s13063-021-05444-w","article-title":"The chinese herbal formula huoxiang zhengqi for diarrhea-predominant irritable bowel syndrome (CHAIRS): a study protocol for a double-blinded randomized controlled trial.","volume":"22","author":"Guo","year":"2021","journal-title":"Trials"},{"key":"R15-20251226","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/jicm.2022.0672","article-title":"Huo xiang zheng qi oral liquid combined with 5-HT3 receptor antagonists and dexamethasone can prevent chemotherapy-induced nausea and vomiting for patients receiving multiday cisplatin-based regimen: a multicenter trial.","volume":"29","author":"Wei","year":"2023","journal-title":"J Integr Complementary Med"},{"key":"R16-20251226","first-page":"3729","article-title":"Psychometric assessment of the chinese version of the MASCC antiemesis tool (MAT) for measuring chemotherapy-induced nausea and vomiting.","volume":"24","author":"Tan","year":"2016","journal-title":"Support Care Cancer"},{"key":"R17-20251226","first-page":"2589","article-title":"Symptom clusters of gastrointestinal cancer patients undergoing radiotherapy using the functional living index\u2014emesis (FLIE) quality-of-life tool.","volume":"23","author":"Poon","year":"2015","journal-title":"Supportive Care Cancer"},{"key":"R18-20251226","first-page":"87","article-title":"ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients.","volume":"27","author":"Razvi","year":"2019","journal-title":"Supportive Care Cancer"},{"key":"R19-20251226","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00432-021-03554-1","article-title":"Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in sichuan, china.","volume":"147","author":"Sun","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"R20-20251226","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/14656566.2013.776541","article-title":"Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.","volume":"14","author":"Janelsins","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"R21-20251226","doi-asserted-by":"crossref","first-page":"105126","DOI":"10.1016\/j.phrs.2020.105126","article-title":"Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: a randomized controlled trial.","volume":"161","author":"Xiao","year":"2020","journal-title":"Pharmacol Res"},{"key":"R22-20251226","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3389\/fphar.2018.01448","article-title":"Systems pharmacology dissection of multi-scale mechanisms of action of huo-Xiang-Zheng-Qi formula for the treatment of gastrointestinal diseases.","volume":"9","author":"Zhao","year":"2019","journal-title":"Front Pharmacol"},{"key":"R23-20251226","doi-asserted-by":"crossref","first-page":"175379","DOI":"10.1016\/j.ejphar.2022.175379","article-title":"Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting.","volume":"936","author":"Chen","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"R24-20251226","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/SPC.0000000000000348","article-title":"Chinese herbal medicines in the prevention and treatment of chemotherapy-induced nausea and vomiting.","volume":"12","author":"Lv","year":"2018","journal-title":"Curr Opinion Support Palliative Care"},{"key":"R25-20251226","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2009.04.063","article-title":"Effects of triterpenoids from poria cocos wolf on the serotonin type 3A receptor-mediated ion current in xenopus oocytes.","volume":"615","author":"Lee","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"R26-20251226","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.3390\/microorganisms12081602","article-title":"Protective effects of huo xiang zheng qi liquid on clostridioides difficile infection on C57BL\/6 mice.","volume":"12","author":"Chen","year":"2024","journal-title":"Microorganisms"},{"key":"R27-20251226","first-page":"1019","article-title":"Toxic medicine used in traditional chinese medicine for cancer treatment: are ion channels involved?","volume":"42","author":"Liu","year":"2022","journal-title":"J Tradit Chin Med"},{"key":"R28-20251226","doi-asserted-by":"crossref","first-page":"106443","DOI":"10.3748\/wjg.v31.i20.106443","article-title":"Harnessing traditional medicine and biomarker-driven approaches to counteract trichostatin a-induced esophageal cancer progression.","volume":"31","author":"Liu","year":"2025","journal-title":"World J Gastroenterol"},{"key":"R29-20251226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2017.07.071","article-title":"Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1\/2 and p38 signaling activation.","volume":"94","author":"Wu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"R30-20251226","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3892\/etm.2017.4128","article-title":"Icariin improves osteoporosis, inhibits the expression of PPAR\u03b3, C\/EBP\u03b1, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats.","volume":"13","author":"Liu","year":"2017","journal-title":"Exp Therap Med"},{"key":"R31-20251226","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13020-024-01018-5","article-title":"Identification of molecular targets of hypericum perforatum in blood for major depressive disorder: a machine-learning pharmacological study.","volume":"19","author":"Xu","year":"2024","journal-title":"Chin Med"},{"key":"R32-20251226","doi-asserted-by":"crossref","first-page":"105626","DOI":"10.1016\/j.jff.2023.105626","article-title":"Syzygium aromaticum enhances innate immunity by triggering macrophage M1 polarization and alleviates helicobacter pylori-induced inflammation.","volume":"107","author":"Peng","year":"2023","journal-title":"J Funct Foods"},{"key":"R33-20251226","doi-asserted-by":"crossref","first-page":"103904","DOI":"10.5500\/wjt.v15.i3.103904","article-title":"Role of traditional chinese medicine in supporting liver transplantation outcomes.","volume":"15","author":"Liu","year":"2025","journal-title":"World J Transplant"},{"key":"R34-20251226","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1007\/s12032-011-0068-9","article-title":"Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival.","volume":"29","author":"Guo","year":"2012","journal-title":"Med Oncol"},{"key":"R35-20251226","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jand.2023.09.003","article-title":"Effect of a standardized ginger root powder regimen on chemotherapy-induced nausea and vomiting: a multicenter, double-blind, placebo-controlled randomized trial.","volume":"124","author":"Crichton","year":"2024","journal-title":"J Acad Nutr Diet"},{"key":"R36-20251226","doi-asserted-by":"crossref","first-page":"117853","DOI":"10.1016\/j.jep.2024.117853","article-title":"Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: a prospective randomized controlled trial.","volume":"325","author":"Wu","year":"2024","journal-title":"J Ethnopharmacol"},{"key":"R37-20251226","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.3802\/jgo.2017.28.e44","article-title":"Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02).","volume":"28","author":"Ohnishi","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"R38-20251226","doi-asserted-by":"crossref","first-page":"116882","DOI":"10.1016\/j.jep.2023.116882","article-title":"Xiao-ban-xia decoction mitigates cisplatin-induced emesis via restoring PINK1\/parkin mediated mitophagy deficiency in a rat pica model.","volume":"318","author":"Zhao","year":"2024","journal-title":"J Ethnopharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046778","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:24:23Z","timestamp":1785857063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":38,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046778","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"2025-09-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}